5 参考文献
1 Carlsten H. Interaction with estrogen receptors as treatment of arthritis and osteoporosis. Adv Exp Med Biol. 2007;602:83-92
2 Novack DV. Estrogen and bone: osteoclasts take center stage. CellMetab 2007;6(4):254-256
3 Gupta G, Aronow WS. Treatment of postmenopausal osteoporosis.Compr Ther 2007;33(3):114-119
4 赵伟业，董碧蓉.骨质疏松药物治疗的新进展及循证证据[J].中国骨质疏松杂志,2003，9(1)：80-83
5 Kanis JA, Adams J, Borgstr?m F,et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008;42(1):4-15
6 Whitfield JF, Mormey PS. Small bone-building fragments of parathyroid homone: New therapeutic agents for osteoporosis . Trend Pharmacol Sci 1995;16:382-395
7 Anbinder AL, Prado Fde A, Prado Mde A,et al. The influence of ovariectomy, simvastatin and sodium alendronate on alveolar bone inrats. Braz Oral Res 2007;21(3):247-252
8 Schousboe JT, Taylor BC, Fink HA,et al.Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men.JAMA 2007;298(6):629-637
9 史轶肇.协和内分泌和代谢学[J].北京:科学出版社,1999:1506-1510
10 潘天鹏,石津生.现代系统老年医学[J].北京:科学出版社,1998:539-534
11 刘汴生,张思雄.实用临床老年病学[J].北京:中国医药科技出版社,2001:553-555
12 王继槐. 阿法骨化醇的药理与临床[J]. 中国药房, 1997,8(1):40
13 Maki K, Nishida I, Kimura M. The effect of oral ipriflavone on the ratmandible during growth. Eur J Orthod 2005;27(1):27-31
14 杨平安,张美兰.绝经后糖尿病妇女骨质疏松症临床观察[J].山西医药杂志,2006;35(2):165-166
15 Levine JP. Pharmacologic and nonpharmacologic management of osteoporosis. Clin Cornerstone 2006;8(1):40-53
16 薛延,杨欣,阮祥燕.骨质疏松症的药物治疗[J]. 中国全科医学,2005,8(16):8-10
17 王福权, 蔡恒江, 茅皖如, 等.男性老年性骨质疏松症发生率与防治的研究[J]. 中华骨科杂志, 1999,19(7):389-392
18 徐建春,毛应德龙,史晓林,等.骨质疏松症的研究进展与展望.浙江临床医学,2006:8(1):40-53
19 余自成.骨质疏松症预防和治疗的药物选择[J].上海医药,2004,25(5):2
20 Uzawa T, Hori M, Ejiri S,et al.Comparison of the effects of intermittent and continuous administration of human parathyroid hormone (1-34) onrat . Bone 1995;16(4):477
21 Silverberg SJ, Gartenberg F, Jacobs TP, et al. Longitudinal measurements of bone density and biochemical indices in untreated primary hyperparathyroidism. J Clin endocrinol Metab 1995;80:723
22 赵冀伟.骨质疏松药物治疗概述[J].天津药学,2004,16(2):683
23 Jó dar-Gimeno E. Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women. Clin Interv Aging.2007;2(1):163-174
24 李异龙,林燕萍.雄激素与原发性骨质疏松相互关系的研究综述.附件中医学院学报,2006:16(1):64-66
25 郑和昕,江缨,袁放,等.血清性激素水平在老年男性原发性骨质疏松症中的变化[J].临床内科杂志,2006,23(2):121-123
26 Khosla S,Melton LJ 3rd,Robb RA,et al.Relationship of volumetric BMD andstructural parameters at different skeletal sites to sex steroid levels in men. J BoneMiner Res 2005; 20: 7302740
27 Pinkerton JV, Dalkin AC. Combination therapy for treatment of osteoporosis: A review. Am J Obstet Gynecol 2007;197(6):559-565
28 Maclean C, Newberry S, Maglione M,et al. Systematic Review:Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis. Ann Intern Med
2007 Dec 17 [Epub ahead of print]
29 Moro Alvarez MJ, Dí az-Curiel M. Pharmacological treatment of osteoporosis for people over 70. Aging Clin Exp Res2007;19(3):246-254
30 陆声, 常山. 骨质疏松药物治疗的新进展[J]. 中国矫形外科杂志,2001,(9)8:912

来源：中国组织工程研究与临床康复  作者：胡春明 孙大辉 张伟 林崇明 莫丽娟